Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BECONASE vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
FDA-approved: Management of seasonal or perennial allergic rhinitis,Off-label: Nonallergic rhinitis, nasal polyps, adjunctive treatment for sinusitis
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
1.5-3 hours (terminal elimination half-life); no accumulation with once-daily dosing.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hydrolyzed by esterases in the lung, liver, and plasma to its active metabolite beclomethasone-17-monopropionate (17-BMP). Further metabolism via CYP3A4 to inactive metabolites.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Primarily hepatic metabolism; <10% excreted renally as unchanged drug; biliary/fecal excretion accounts for minimal elimination.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
87% bound to plasma proteins, primarily corticosteroid-binding globulin and albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.5-1.5 L/kg; indicates extensive distribution into tissues.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Intranasal: <1% systemic absorption due to extensive first-pass metabolism and local administration.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No adjustment required.
No adjustment required as drug is primarily hepatically metabolized.
No adjustment required.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Children 6-11 years: 1 spray (42 mcg) per nostril twice daily; children ≥12 years: same as adult.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
No specific adjustment; use lowest effective dose.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None
None.
Risk of suppression of hypothalamic-pituitary-adrenal (HPA) axis with prolonged use at higher than recommended doses,Possible development of localized Candida albicans infections of the nose and pharynx,Caution in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex,Use with caution in patients with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to beclomethasone dipropionate or any component of the formulation,Untreated localized nasal mucosal infections (e.g., herpes simplex)
Hypersensitivity to theophylline or any component of the formulation.
No specific food interactions reported. Beconase is administered intranasally and has negligible systemic absorption, so dietary restrictions are not required.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major congenital malformations or adverse fetal outcomes. However, the potential for fetal harm cannot be completely ruled out. Trimester-specific risks: First trimester: No evidence of teratogenicity in animal studies at clinically relevant doses, but human data are limited. Second and third trimesters: No increased risk of fetal growth restriction or adrenal suppression reported, but high doses may theoretically affect fetal adrenal function.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Inhaled beclomethasone is not expected to be present in breast milk in significant amounts due to low systemic bioavailability. The M/P ratio is not available. Manufacturer advises caution, but risk to infant is low. Use while breastfeeding is considered acceptable if maternal benefit outweighs potential risk.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No dose adjustment is generally required for inhaled beclomethasone during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered clearance) are not clinically significant for inhaled corticosteroids due to minimal systemic absorption. However, ensure the lowest effective dose is used to maintain asthma control.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Beconase (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Onset of action is not immediate; regular use for several days to weeks is required for full effect. Priming the nasal spray with 6 sprays before first use is essential. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. For best results, administer after clearing nasal passages. Systemic absorption is minimal at recommended doses, but monitor for growth suppression in children with prolonged high-dose use.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Use Beconase regularly as prescribed, not for immediate symptom relief.,Prime the spray with 6 test sprays before first use or if not used for 7 days.,Blow nose gently before dosing to clear nasal passages.,Tilt head forward, insert nozzle into nostril, and spray away from the septum.,Avoid spraying into eyes or on the nasal septum.,Do not exceed recommended dosage; side effects are rare but include nasal irritation or nosebleeds.,Inform your doctor if symptoms do not improve after 3 weeks.,If also using a decongestant spray, use the decongestant first, then wait 10-15 minutes before Beconase.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BECONASE vs AEROLATE JR, answered by our medical review team.
BECONASE is a Nasal Corticosteroid that works by Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BECONASE and AEROLATE JR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BECONASE is: 1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BECONASE and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BECONASE is classified as Category C. Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major co. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.